Slide 1: Investor Presentation May 2025
Not for distribution or release in the United States For personal use only Investor Presentation May 2025
Slide 2: Disclaimer and important notice
Disclaimer and important notice This presentation has been prepared by TruScreen Group Limited (TRU). This presentation has been prepared in relation to the offer of new shares in TRU (New Shares) by way of a: • Placement to selected investors in certain jurisdictions (Placement); and • Share Purcha
Slide 3: Disclaimer and important notice (continued)
Disclaimer and important notice (continued) Future performance (continued): The forward-looking statements are based on information available to TRU as at the date of this presentation. Except as required by law or regulation (including the NZX and ASX Listing Rules) TRU undertakes no obligation to
Slide 4: Disclaimer and important notice (continued)
Disclaimer and important notice (continued) Distribution of presentation: This presentation (including an electronic copy) must not be distributed in any jurisdiction to the extent that its distribution in that jurisdiction is restricted or prohibited by law or would constitute a breach by TRU of an
Slide 5: For personal use only
Who is TruScreen The TruScreen Technology For personal use only Why TruScreen TruScreen Sales Strategy and Markets TruScreen Highlights CY 24 – CY25 TruScreen Outlook: FY26 and Beyond TruScreen Options Key Terms
Slide 6: Who is TruScreen
Who is TruScreen Dual listed on the Australian (ASX) (foreign exempt listing) and New Zealand (NZX) stock exchanges, with a common ticker code of TRU. For personal use only TruScreen Group Ltd is a revenue generating Life Science company with FY25 annual sales of NZ$ 1.7m, down from $2.1m in FY24. T
Slide 7: Key Financials and TRU Price History
Key Financials TRU Price History (NZX) As at 28 May 2025 Market Cap: For personal use only NZ $16.09M Share Price: AU$0.027 / NZ$0.029 Cash Balance (pro-forma): NZ$365,000 Issued Capital: 554,907,719 Current Holders: 1942 7
Slide 8: An Experienced Leadership Team
An Experienced Leadership Team Mr. Anthony Ho Mr. Christopher Horn B. Com (UNSW), CA, FAICD, B. Com (UNSW), FCA FCIS, FGIA For personal use only Non-executive Independent Director Non-executive Chairman • Currently a Director and Chairman of a number of listed ASX • Involved with TruScreen for a num
Slide 9: An Experienced Leadership Team
An Experienced Leadership Team Ms. Juliet Hull Dr. Dexter Cheung B.Nurse ATI, MBA MGSM B. Tech (Hons), M.Eng, PHD For personal use only Non-executive Director Non-executive Director • MBA from the Macquarie Graduate School of Management, • Experienced medical device engineer and specialist in produc
Slide 10: An Experienced Leadership Team
An Experienced Leadership Team Martin Dillon Mr. Guy Robertson Professor Michael B. Com (Hons.) CA Campion CEO CFO & Company Medical Advisory For personal use only Secretary Committee Chair • Martin Dillon, the CEO of TruScreen Group Ltd, • Guy is an experienced finance executive, having held • Univ
Slide 11: The TruScreen Journey
The TruScreen Journey Building the Fundamentals 2014 - 2020 Building for the Future 2020-2024 2025 & Beyond For personal use only China Growth continues 2022 Recognition by World Health Managing COVID-19 challenges Distribution of Dalton Bio IVD HPV DNA products CFDA (NMPA) 523% sales Organization C
Slide 12: The TruScreen Technology
For personal use only The TruScreen Technology
Slide 13: For personal use only
• Enabled by AI, TruScreen provides an accurate, real time cervical cancer screening solution • Each TruScreen examination takes one to two minutes to produce results, compared to conventional Pap tests which can take days, weeks, or even months in some countries, for a result to be returned. For pe
Slide 14: How it works
How it works 1 a pen-like wand covered by a Single Use Sensor (SUS) is used For personal use only to gently touch multiple spots on the cervix. The SUS contains a precision lens and electrodes which interfaces with the cervix. It sends and picks up low level electrical and optical signals (14 readin
Slide 15: How it works
How it works 2 The TruScreen Handheld Device (HHD) then applies an integrated AI-enabled algorithm to analyse these For personal use only signals and compares them to an integrated database of 2,000 patients drawn from a wide range of geographic and ethnic backgrounds with differing histological dia
Slide 16: For personal use only
✓ Clinicians/physicians are able to immediately plan appropriate patient care ✓ Device has an expected life span of 5–7 years ✓ Disposable SUS is used once per test per patient - ensures For personal use only there is no chance of cross-infection between patients ✓ The entire patient data collection
Slide 17: Why TruScreen?
For personal use only Why TruScreen?
Slide 18: Extensive body of clinical evidence
Extensive body of clinical evidence Over 40,000 women in clinical trials to date*** For personal use only Year Country Investigator N Year Country Investigator N 2002 China Dr Huang Yi 683 2019 China Dr. Baojin Wang 315 2002 China Dr Wang Ziyao 301 2019 China Dr. Wei Zhang 1030 2003 UK/Aus Prof A. S
Slide 19: COGA Trial
COGA Trial (n= 15,661, 2018-2021) 4 • TruScreen specificity surpassed Liquid Based Cytology (LBC) and hrHPV • TruScreen was determined to be a simple, effective and rapid real-time cervical cancer screening method • TruScreen was determined to be an appropriate primary cervical cancer screening tool
Slide 20: Why TruScreen?
Why TruScreen? Truscreen Liquid Based Cytology (LBC) HPV DNA Real time results For personal use only Low infrastructure costs Strong clinical results Objective results Low training threshold Portable No cell or tissue samples taken 20
Slide 21: TruScreen Sales Strategy and Markets
For personal use only TruScreen Sales Strategy and Markets
Slide 22: TruScreen Sales Strategy
TruScreen Sales Strategy • TruScreen focuses on emerging economies such as China, India, Indonesia, Mexico, Uzbekistan, Vietnam and Zimbabwe. Unlike the developed western markets, these countries For personal use only have no or minimal large-scale cervical cancer screening programs and infrastructu
Slide 23: Recurring Revenue Model
Recurring Revenue Model • TruScreen manufactures two devices – o one made in China for use in China, where locally manufactured products have For personal use only preferential market access o one made in Australia for other markets • For each patient screened with the TruScreen device a new disposa
Slide 24: Entry into Public Screening Programs
Entry into Public Screening Programs • TruScreen’s sales to date have been achieved largely through traditional sales of devices and Single Use Sensors to hospitals and clinics. In FY25 these traditional channels made up 99% For personal use only of sales. • Following the previous success of TruScre
Slide 25: TruScreen's presence and global markets
TruScreen’s presence and global markets RUSSIA 48M, CENTRAL ASIA For personal use only 13M China UZBEKISTAN 477M MEXICO SAUDI 12M 46M 11M VIETNAM 36M ASEAN & INDONESIA 142M SOUTHERN INDIA & CENTRAL 468M Existing market AFRICA 134M Target market 25
Slide 26: TruScreen Regulatory Approvals
TruScreen Regulatory Approvals International Quality Recognized by International Approvals: Accreditation: World Health Organisation (WHO) • CE Mark, European Union For personal use only UNITAID • NMPA, China ISO 13485 • TGA, Australia Clinton Health Access Initiative ISO 60601-1-2 • MHRA, UK Daffod
Slide 27: TruScreen Highlights CY24 - CY25
For personal use only TruScreen Highlights CY24 - CY25
Slide 28: TruScreen and Dalton BioScience
TruScreen and Dalton BioScience MOU signed February 2025 between TruScreen Group Ltd and Hangzhou Dalton Bioscience For personal use only • TruScreen to distribute globally (excluding USA and Canada) via selected distributors DaltonBio HPV related IVD products including DNA tests and Self Sampling.
Slide 29: Key market China exceeded budget and poised for expansion
Key market China, accounting for over 85% of global sales, exceeded budget and is poised for expansion in 6 key provinces • Key provinces for growth: TruScreen’s China distributor Beijing Siweixiangtai Technology Co Ltd (SWXT) is targeting 6 key provinces for growth in FY26 - Guangxi, For personal u
Slide 30: For personal use only
• Private Sector Expansion: SWXT targeting of the growing China private health sector including private clinic and Health Check Centre approvals in Jiangsu and Shenzhen, and entry into the Luxury Hospital and Traditional Chinese Medicine Hospital sectors. • Public Health Insurance: In addition to ha
Slide 31: Selected to screen 260,000 women in Ho Chi Minh City
TruScreen selected to screen 260,000 women in Ho Chi Minh City and adoption in Vietnam picks up pace • The formal agreement to conduct a 5-year program to screen 260,000 women for cervical cancer in Ho Chi Minh City was signed in April 2025 For personal use only Following the signing of a Memorandum
Slide 32: TruScreen re-enters India with Renovate Biologicals
TruScreen re-enters India with appointment of Renovate Biologicals Pvt Ltd in April 2025 India holds one-sixth of the world's population and one woman dies from cervical cancer every eight minutes in the country. For personal use only The cervical cancer screening rate is only 2%, and India’s Nation
Slide 33: Indonesia product registration completed and distributor appointed
Indonesia product registration completed and distributor appointed, with commercial activity commenced in May 2025 • Distributor Appointed: Following the completion of product registration, INDONESIA For personal use only TruScreen appointed a new Indonesian medical products distributor PT 96 millio
Slide 34: Results validated by independent studies and WHO
TruScreen results and suitability in emerging markets continues to be validated by independent studies and the World Health Organization • October 2024 – UNITAID included TruScreen in its technology landscape report “Screening and For personal use only treatment of pre-cancerous lesions for secondar
Slide 35: For personal use only
• November 2024 – following the UNITAID inclusion, TruScreen were invited to present at the World Health Organisation (WHO) key meeting to further the use of AI technologies for screening of cervical cancer in Edinburgh, and were the only opto-electric tissue differentiating medical device company i
Slide 36: TruScreen Outlook: FY26 and beyond
For personal use only TruScreen Outlook: FY26 and beyond
Slide 37: FY25 Sales (Actual) and FY26 Sales (Projection)
FY25 Sales (Actual) FY26 Sales (Projection) NZ$ 1.71m NZ$ 2.8m Projected +64% YOY increase with increased diversification of revenue For personal use only This slide contains forward-looking information and should be read in conjunction with the important information on pages 2 – 4 of this presentat
Slide 38: TruScreen Expected Sales Increase FY26
TruScreen Expected Sales Increase FY26 NZ$ 2.8m Public Screening Expected sales Six key Program to Public > NZ$ 100k provinces resume; Screening to For personal use only Ho Chi Minh targeted; Expected sales commence; City Public Expected sales > NZ$ 300k Dalton Bio IVD Expected sales Screening incre
Slide 39: Growth Strategies
Growth Strategies Market expansion to continue with Strengthen vertical Asian market from China the key focus Indonesia through China, and capitalise on Indian distribution network For personal use only Focus on key growth provinces (Shandong, Target Govt and NGO funded Jiangsu,, Hunan, Zhejiang, Gu
Slide 40: Growth Strategies (cont.)
Growth Strategies (cont.) Focus on countries with limited or nil Expand product portfolio to include Dalton cervical screening capability Bio HPV related IVD products DNA tests, including HPV DNA tests and self sampling For personal use only Developing strategic partnerships for Reduce SUS and Devic
Slide 41: TruScreen Options Key Terms
For personal use only TruScreen Options Key Terms:
Slide 42: Attached Share Option
Attached Share Option Subject to Shareholder approval by way of an ordinary resolution at a special meeting of TruScreen shareholders, Eligible Shareholders who participate in the SPP or the Placement will also receive an unlisted option (“Share Option”) with the following rights and liabilities: (a
Slide 43: For personal use only
(e) Exercise Notice: An Optionholder may exercise their Share Options at any time before they lapse by lodging with the Company: i. a written notice of exercise of Share Options specifying the number of Share Options being exercised (“Exercise Notice”); and ii. electronic funds transfer for the Exer
Slide 44: For personal use only
(h) Shares issued on exercise: All Shares issued upon the exercise of any Share Options will upon issue rank pari passu in all respects with other Shares. For personal use only (i) Share Options not transferable: The Share Options are not transferable. (j) Quotation of Share Options: The Company wil
Slide 45: For personal use only
(l) Participation in new issues: There are no participation rights or entitlements inherent to the Share Options and the Optionholders will not be entitled to participate in new issues of capital offered to Shareholders during the currency of the Share Options (unless the relevant Share Options have
Slide 46: Contact us for more Information
Contact us for more Information For personal use only Martin Dillon Guy Robertson CEO Chief Financial Officer M - +61 449 115 065 M – +61 407 983 270 E – martindillon@truscreen.com E – guyrobertson@truscreen.com TruScreen TruScreen Suite 3.03 18 Orion Rd Suite 3.03 18 Orion Rd Lane Cove West NSW 206